natgillin/translations-raw huggingface dataset:
Patients on chemotherapy who experienced independently verified progression of disease after the first scheduled disease assessment were able to crossover and receive 2 mg/kg or 10 mg/kg of pembrolizumab every 3 weeks in a double blind fashion.
Bolniki na kemoterapiji, pri katerih je po prvi predvideni oceni bolezni po 12 tednih zdravljenja prišlo do napredovanja bolezni, ki je bilo neodvisno potrjeno, so lahko prešli na dvojno slepo prejemanje 2 mg/kg ali 10 mg/kg pembrolizumaba na tedne.
Patients on dabigatran etexilate who undergo surgery or invasive procedures are at increased risk for bleeding.
Pri bolnikih, ki jemljejo dabigatran eteksilat, obstaja med kirurškimi posegi ali invazivnimi postopki povečano tveganje krvavitve.
Patients on hydroxycarbamide should be made aware of the theoretical risks to the foetus.
Bolnice, ki se zdravijo s hidroksikarbamidom, je treba opozoriti na teoretično tveganje za zarodek.
Patients on hydroxycarbamide wishing to conceive should stop treatment 3 to 6 months before pregnancy if possible.
Bolnice, ki želijo zanositi, morajo z zdravljenjem prekiniti 3 do 6 mesecev preden je možna zanositev.
Patients on imatinib treatment who are concerned about their fertility should consult with their physician.
Bolniki, ki jih skrbi glede njihove plodnosti v času zdravljenja z imatinibom, naj se posvetujejo s svojim zdravnikom.
Patients on metformin and sulphonylurea: when appropriate AVANDAMET may be initiated at 4 mg/day rosiglitazone with the dose of metformin substituting that already being taken.
Bolniki, ki se zdravijo z metforminom in s sulfonilsečnino: če je primerno, se zdravilo AVANDAMET lahko uvede v odmerku 4 mg/dan rosiglitazona in odmerku metformina, ki zamenja odmerek metformina, ki ga bolnik že jemlje.
Patients on oral antidiabetic agents receiving Bortezomib Hospira treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetics.
Pri bolnikih, ki so prejemali peroralne antidiabetike in bortezomib, je potrebno skrbno spremljanje koncentracije glukoze v krvi in prilagoditi odmerek antidiabetika.
Patients on Revestive maintained their previous dose assignment throughout the extension phase, while placebo patients were randomised to active treatment, either 0.05 or 0.10 mg/kg/day.
Bolniki na zdravilu Revestive so tudi v podaljšani fazi prejemali svoj prejšnji odmerek, medtem ko so bili bolniki s placebom randomizirani v dve skupini z aktivnim zdravljenjem, bodisi po 0,05 ali po 0,10 mg/kg/dan.
Patients on temsirolimus who develop thrombocytopaenia may be at increased risk of bleeding events, including epistaxis (see section 4.8).
Pri bolnikih, ki prejemajo temsirolimus in pri katerih se razvije trombocitopenija, obstaja večje tveganje za pojav krvavitev, vključno z epistakso (glejte poglavje 4.8).
Patients on temsirolimus with baseline neutropaenia may be at risk of developing febrile neutropaenia.
Pri bolnikih, ki prejemajo temsirolimus in imajo izhodiščno nevtropenijo, obstaja tveganje za razvoj febrilne nevtropenije.
Patients on the comparator arm received cisplatin (P) 100 mg/m² as a 30-minute to three-hour intravenous infusion on day 1 followed by the continuous intravenous infusion of 5-fluorouracil (F) 1,000 mg/m²/day from day 1 to day 5.
Bolniki v primerjalnem kraku so prvi dan dobili cisplatin (P) 100 mg/m2 v 30-minutni do 3-urni intravenski infuziji in nato stalno intravensko infuzijo 5-fluorouracila (F) 1000 mg/m2/dan od 1. do 5. dneva.
Patients on the comparator arm received cisplatin (P) 100 mg/m² as a 30-minute to three-hour intravenous infusion on day 1 followed by the continuous intravenous infusion of 5-fluorouracil (F) 1000 mg/m²/day from day 1 to day 5.
Bolniki v primerjalnem kraku so dobili cisplatin (P) 100 mg/m2, ki mu je sledil 5-fluorouracil (F) 1000 mg/m2 na dan 5 dni.
Patients on the docetaxel arm received docetaxel (T)
Bolniki v kraku z docetakselom so prejeli docetaksel (T) 75 mg/m2, ki mu je sledil cisplatin (P)
Patients on the docetaxel arm received docetaxel (T) 75 mg/m2 followed by cisplatin (P) 75 mg/m2 followed by
Bolniki v kraku z docetakselom so dobivali docetaksel (T) 75 mg/m2, ki mu je sledil cisplatin
Patients on the docetaxel arm received docetaxel (T) 75 mg/m2 followed by cisplatin (P) 75 mg/m2 followed by
Bolniki v kraku z docetakselom so prejeli docetaksel (T) 75 mg/m2, ki mu je sledil cisplatin (P) 75 mg/m2, temu pa
Patients on the docetaxel arm received docetaxel (T) 75 mg/m2 followed by cisplatin (P) 75 mg/m2 followed by fluorouracil (F) 750 mg/m2 per day as a continuous infusion for 5 days.
Bolniki v kraku z docetakselom so dobivali docetaksel (T) 75 mg/m2, ki mu je sledil cisplatin (P) 75 mg/m2, temu pa 5-fluorouracil (F) 750 mg/m2 dnevno v obliki neprekinjene infuzije 5 dni.
Patients on the docetaxel arm received docetaxel (T) 75 mg/m² by intravenous infusion on day 1 followed by cisplatin (P)
Bolniki v kraku z docetakselom so dobili docetaksel (T) 75 mg/m2 v intravenski infuziji
Patients on the docetaxel arm received docetaxel (T) 75 mg/m² by intravenous infusion on day 1 followed by cisplatin (P)
Bolniki v kraku z docetakselom so dobili docetaksel (T) 75 mg/m2 v intravenski infuziji 1. dan, ki mu je sledil cisplatin (P) 100 mg/m2 v 30-minutni do 3-urni intravenski infuziji in nato stalna intravenska infuzija
Patients on the docetaxel arm received docetaxel (T) 75 mg/m² by intravenous infusion on day 1 followed by cisplatin (P) 100 mg/m² administered as a 30-minute to three-hour intravenous infusion, followed by the continuous intravenous infusion of 5-fluorouracil (F) 1,000 mg/m²/day from day 1 to day 4.
Bolniki v kraku z docetakselom so dobili docetaksel (T) 75 mg/m2 v intravenski infuziji 1. dan, ki mu je sledil cisplatin (P) 100 mg/m2 v 30-minutni do 3-urni intravenski infuziji in nato stalna intravenska infuzija 5- fluorouracila (F) 1000 mg/m2/dan od 1. do 4. dneva.
Patients on the docetaxel arm received docetaxel (T) 75 mg/m² by intravenous infusion on day 1 followed by cisplatin (P) 100 mg/m² administered as a 30-minute to three-hour intravenous infusion, followed by the continuous intravenous infusion of 5-fluorouracil (F) 1000 mg/m²/day from day 1 to day 4.
Bolniki v kraku z docetakselom so dobili docetaksel (T) 75 mg/m2 v intravenski infuziji 1. dan, ki mu je sledil cisplatin (P) 100 mg/m2 v 30-minutni do 3-urni intravenski infuziji in nato stalna intravenska infuzija 5- fluorouracila (F) 1000 mg/m2/dan od 1. do 4. dneva.
Patients on treatment with potent inhibitors of OATP1B1 (e.g. cyclosporine)
Bolniki, ki se zdravijo z močnimi zaviralci OATP1B1 (npr. ciklosporinom).
Patients on Trudexa may receive concurrent vaccinations, except for live vaccines.
Bolniki, ki prejemajo Trudexo, lahko sočasno dobijo cepiva, razen živih cepiv.
Patients on urate lowering therapy (ULT)
Bolniki, ki prejemajo zdravila za zmanjševanje količine urata
Patients or their caregivers should be instructed on the appropriate procedure for disposal of the vials, syringes and needles in accordance with local requirements.
Bolnike oziroma njihove negovalce je treba poučiti o pravilnih postopkih za odstranjevanje vial, brizg in igel v skladu z lokalnimi predpisi.
Patients or their carers can inject the medicine once they have been properly trained by a healthcare professional.
Bolniki ali njihovi negovalci lahko zdravilo injicirajo sami, potem ko jih za to ustrezno usposobi zdravstveni delavec.
Patients or their carers may be able to administer NovoEight themselves at home once they have been trained appropriately.
Bolniki ali njihovi negovalci lahko zdravilo NovoEight dajejo sami doma, če so bili za to ustrezno usposobljeni.
Patients or their carers may be able to administer Nuwiq themselves at home once they have been trained appropriately.
Bolniki ali njihovi negovalci lahko zdravilo Nuwiq dajejo sami doma, če so bili za to ustrezno usposobljeni.
Patients or their carers may be able to administer the treatment themselves at home if their treating physician feels this is appropriate and once they have been trained appropriately.
Bolniki ali njihovi negovalci lahko po opravljenem usposabljanju zdravilo dajejo doma sami, če se s tem strinja njihov lečeči zdravnik.
Patients over 60 years of age may be at greater risk for mild (>3xULN) to severe (>8xULN) elevation of ALT.
Tveganje za blago (> 3-kratna ZMN) do hudo (> 8-kratna ZMN) zvišanje vrednosti ALT je lahko večje pri bolnikih, starejših od 60 let.
Patients over 65 years of age and patients who have problems with their liver or kidneys may need a lower starting dose of 5 mg per day.
Bolniki, starejši od 65 let, in bolniki, ki imajo težave z jetri ali ledvicami, bodo morda potrebovali nižji začetni odmerek, 5 mg na dan.
Patients participating in all Phase 2 and Phase 3 psoriasis studies were eligible to enroll into an open- label extension trial, where Humira was given for at least an additional 108 weeks.
Bolniki, ki so sodelovali v študijah psoriaze 2. in 3. faze, so bili lahko vključeni v odprto podaljšano preskušanje, v katerem so zdravilo Humira prejemali vsaj še dodatnih 108 tednov.
Patients participating in Studies HS-I and HS-II were eligible to enroll into an open-label extension study in which Humira 40mg was administered every week.
Bolniki, vključeni v študiji HS-I in HS-II, so bili primerni za vključitev v odprto podaljšano študijo, pri kateri so prejemali zdravilo Humira 40 mg vsak teden.
Patients presenting end stage renal disease (creatinine clearance (CLCR< 15 mL/min/1.73 m2), by their condition and the limited amount of data available should be treated with caution and monitored carefully during treatment (see sections 4.4 and 5.2).
Bolnike s končno fazo ledvične bolezni (očistek kreatinina je manjši od 15 ml/min/1.73 m2 ) je treba glede na njihovo stanje in zaradi maloštevilnih dostopnih podatkov zdraviti previdno in jih med zdravljenjem natančno kontrolirati (glejte poglavji 4.4 in 5.2).
Patients presenting with serious lung events that do not respond to conventional antimicrobial therapy should be assessed for drug-induced pneumonitis.
Bolnike z resnimi pljučnimi dogodki, ki se ne odzivajo na običajno protimikrobno zdravljenje, je treba oceniti glede pnevmonitisa zaradi zdravila.
Patients previously exposed to natalizumab should normally wait a minimum of 12 weeks prior to initiating therapy with Entyvio, unless otherwise indicated by the patient’s clinical condition.
Pri bolnikih, ki so se predhodno zdravili z natalizumabom, je pred uvedbo zdravljenja z zdravilom Entyvio običajno treba počakati najmanj 12 tednov, razen če klinično stanje bolnika ne narekuje drugače.
Patients previously Insulin naive or on basal isnulin
Bolniki, ki prej še niso dobivali insulina ali so uporabljali bazalni insulin
Patients previously on other phosphate binders who are switched to BindRen should start taking 6-9 g per day (2-3 g three times daily).
Bolniki, ki so predhodno dobivali druge vezalce fosfatov, sedaj pa so prešli na zdravilo BindRen, naj začnejo z odmerkom 6–9 g na dan (2–3 g trikrat na dan).
Patients previously on other phosphate binders who are switched to Fexeric should start taking 3 to 6 g (3 to 6 tablets) per day.
Bolniki, ki so predhodno jemali druga zdravila, ki vežejo fosfate, in preidejo na zdravilo Fexeric, morajo začeti jemati od 3 do 6 g (od 3 do 6 tablet) na dan.
Patients previously stabilised on different doses of risperidone long acting injection can attain similar paliperidone steady-state exposure during maintenance treatment with Xeplion monthly doses according to the following:
Bolniki stabilizirani na različnih odmerkih dolgodelujoče injekcije risperidona, lahko med vzdrževalnim zdravljenjem z mesečnimi odmerki zdravila Xeplion dosežejo podobno izpostavljenost paliperidonu v stanju dinamičnega ravnovesja, pri čemer je treba upoštevati naslednje:
Patients previously treated with DMARDs or biologics who received apremilast achieved a greater ACR 20 response at Week 16 than patients receiving placebo.
Bolniki, predhodno zdravljeni z DMARDs ali biološkimi zdravili, ki so prejemali apremilast, so po 16 tednih dosegli večji odziv ACR 20 kot bolniki, ki so prejemali placebo.
Patients previously treated with immunoglobulin administered intravenously
Bolniki, ki so bili predhodno zdravljeni z imunoglobulini, uporabljenimi intravensko
Patients previously treated with immunoglobulin administered subcutaneously
Bolniki, ki so bili predhodno zdravljeni z imunoglobulini, uporabljenimi subkutano
Patients randomised
Število
Patients randomised to 100 mg BID + OBR
Bolniki, randomizirani v skupino 100 mg dvakrat na dan + OBR
Patients randomised to 5-FU/LV received leucovorin 200 mg/m2 intravenously over 30 minutes, followed by 5-FU 2,000 mg/m2 intravenously over 24 hours, administered on Days 1, 8, 15 and 22 of a 6 week cycle.
Bolniki, randomizirani na 5-FU/LV, so prejemali levkovorin v odmerku 200 mg/m2 s 30-minutno intravensko infuzijo, ki ji je sledila 24-urna intravenska infuzija 5-FU v odmerku 2.000 mg/m2, kar so prejemali 1., 8., 15. in 22. dan 6-tedenskega cikla.
Patients randomised to Cosentyx received 10 mg/kg intravenously at Weeks 0, 2, and 4, followed by either 75 mg or 150 mg subcutaneously every month starting at Week 8.
Bolniki, ki so jih randomizirali na prejemanje zdravila Cosentyx, so ga prejemali v odmerku 10 mg/kg intravensko enkrat na teden v tednih 0, 2 in 4, nato pa bodisi 75 mg ali 150 mg subkutano enkrat na mesec, kar se je začelo v tednu 8.
Patients randomised to Cosentyx received 150 mg or 300 mg doses at Weeks 0, 1, 2, and 3, followed by the same dose every month starting at Week 4.
Bolniki, ki so bili randomizirani na prejemanje zdravila Cosentyx, so prejeli odmerke 150 mg oziroma 300 mg v tednih 0, 1, 2 in 3, nato pa enak odmerek enkrat na mesec z začetkom v tednu 4.
Patients randomised to Cosentyx received 75 mg or 150 mg subcutaneously at Weeks 0, 1, 2, and 3, followed by the same dose every month starting at Week 4.
Bolniki, ki so jih randomizirali na prejemanje zdravila Cosentyx, so ga prejemali v odmerku 75 mg ali 150 mg subkutano enkrat na teden v tednih 0, 1, 2 in 3, nato pa so enak odmerek prejemali vsak mesec, kar se je začelo v tednu 4.
Patients randomised to Cosentyx received 75 mg, 150 mg or 300 mg subcutaneously at Weeks 0, 1, 2, and 3, followed by the same dose every month starting at Week 4.
Bolniki, ki so jih randomizirali na prejemanje zdravila Cosentyx, so ga prejemali v odmerkih 75 mg, 150 mg ali 300 mg subkutano enkrat na teden v tednih 0, 1, 2 in 3, nato pa so enak odmerek prejemali enkrat na mesec z začetkom v tednu 4.
Patients randomised to either arm were to continue treatment until disease progression (defined as confirmed radiographic progression or the occurrence of a skeletal-related event) and initiation of new systemic antineoplastic treatment, unacceptable toxicity, or withdrawal.
Bolniki, randomizirani v en ali drug krak, so nadaljevali zdravljenje do napredovanja bolezni (ki je bilo opredeljeno kot radiografsko potrjeno napredovanje ali pojav z okostjem povezanega dogodka) oziroma do uvedbe novega sistemskega antineoplastičnega zdravljenja, nesprejemljivih toksičnih učinkov ali umika.
Patients randomised to Galafold in Stage 1 demonstrated statistically significant greater reduction (±SEM) in mean interstitial capillary GL-3 deposition (-0.25±0.10; -39%) at month 6 compared to placebo (+0.07 ± 0.13; +14%) (p=0.008).
Pri bolnikih, ki so bili v fazi 1 randomizirani na zdravilo Galafold, se je srednje odlaganje GL-3 v intersticijskih kapilarah v 6. mesecu v primerjavi s placebom (+0,07 ± 0,13; +14 %) statistično značilno bolj zmanjšalo (±SEM) (–0,25 ± 0,10; –39 %) (p = 0,008).
Patients randomised to ONIVYDE monotherapy received 120 mg/m2 as an intravenous infusion over 90 minutes every 3 weeks.
Bolniki, randomizirani na zdravilo ONIVYDE v monoterapiji, so ga prejemali v obliki 90- minutne intravenske infuzije v odmerku 120 mg/m2 na 3 tedne.
Patients randomised to Placebo + OBR
Bolniki, randomizirani v skupino placebo + OBR
Patients randomised to placebo in Stage 1 and switched to Galafold at month 6 (Stage 2) also demonstrated statistically significant decreases in interstitial capillary GL-3 inclusions at month 12 (-0.33±0.15; -58%) (p=0.014).
Pri bolnikih, ki so bili v fazi 1 randomizirani na placebo in so na zdravilo Galafold prešli v 6. mesecu (faza 2), je bilo vključkov GL-3 v ntersticijskih kapilarah v 12. mesecu prav tako statistično značilno manj (–0,33 ± 0,15; –58 %) (p = 0,014).
Patients randomised to placebo who were non-responders at Week 16 (early rescue) and all other placebo patients at Week 24 were crossed over to receive Cosentyx (either 75 mg or 150 mg subcutaneously), followed by the same dose every month.
Bolniki, ki so bili randomizirani na prejemanje placeba in pri katerih ni prišlo do odziva do tedna 16, so takoj prešli na uporabo zdravila Cosentyx (zgodnje reševanje), vsi drugi bolniki s placebom pa so prešli na uporabo zdravila Cosentyx (bodisi 75 mg ali 150 mg subkutano) v tednu 24, nato pa so enak odmerek prejemali vsak mesec.
Patients randomised to placebo who were non-responders at Week 16 (early rescue) and other placebo patients at Week 24 were crossed over to receive Cosentyx (either 75 mg or 150 mg subcutaneously) followed by the same dose every month.
Bolniki, ki so bili randomizirani na prejemanje placeba in pri katerih ni prišlo do odziva do tedna 16, so takoj prešli na uporabo zdravila Cosentyx (zgodnje reševanje), drugi bolniki s placebom pa so prešli na uporabo zdravila Cosentyx (bodisi 75 mg ali 150 mg subkutano) v tednu 24, nato pa so enak odmerek prejemali vsak mesec.
Patients randomised to receive placebo who were non-responders at Week 16 (early rescue) were crossed over to receive Cosentyx (either 150 mg or 300 mg subcutaneously) at Week 16 followed by the same dose every month.
Bolniki, ki so bili randomizirani na prejemanje placeba in pri katerih ni prišlo do odziva do tedna 16, so takoj prešli na uporabo zdravila Cosentyx (bodisi 150 mg ali 300 mg subkutano) (zgodnje reševanje), nato pa so enak odmerek prejemali vsak mesec.
Patients randomised to receive placebo who were responders at Week 16 were crossed over to receive Cosentyx (either 150 mg or 300 mg subcutaneously) at Week 24 followed by the same dose every month.
Bolniki, ki so bili randomizirani na prejemanje placeba in pri katerih je prišlo do odziva do tedna 16, pa so prešli na uporabo zdravila Cosentyx (bodisi 150 mg ali 300 mg subkutano) v tednu 24, nato pa so enak odmerek prejemali vsak mesec.
Patients randomised to Taltz who were sPGA (0,1) responders at Week 12 were re-randomised to receive placebo or Taltz for an additional 48 weeks (UNCOVER-1 and UNCOVER-2); patients randomised to placebo, etanercept or Taltz who were sPGA (0,1) non-responders received Taltz for up to 48 weeks.
Bolniki, ki so bili randomizirani za uporabo zdravila Taltz, in ki so se odzvali z oceno sPGA (0,1) v 12. tednu, so bili randomizirani za prejemanje placeba ali zdravila Taltz dodatnih 48 tednov (UNCOVER-1 in UNCOVER-2); bolniki, ki so bili randomizirani za uporabo placeba, etanercepta ali zdravila Taltz, ki se niso odzvali z oceno sPGA (0,1), so prejemali zdravilo Taltz še največ 48 tednov.
Patients randomised to vPDT were allowed to receive ranibizumab treatment as of Month 3 (in Group III, 38 patients received ranibizumab as of Month 3)
b primerjalna kontrolna skupina do konca 3. meseca: bolniki, ki so bili randomizirani v skupino s fotodinamično terapijo z verteporfinom, so smeli prejeti ranibizumab po koncu 3. meseca (v skupini III je 38 bolnikov prejelo ranibizumab po koncu 3. meseca)
Patients randomized to ONIVYDE+5-FU/LV received ONIVYDE at 80 mg/m2 as an intravenous infusion over 90 minutes, followed by LV 400 mg/m2 intravenously over 30 minutes, followed by 5-FU 2,400 mg/m2 intravenously over 46 hours, administered every 2 weeks.
Bolniki, randomizirani na zdravilo ONIVYDE+5-FU/LV, so na 2 tedna prejemali zdravilo ONIVYDE v odmerku 80 mg/m2 v obliki 90-minutne intravenske infuzije, ki ji je sledila 30-minutna intravenske infuzija LV v odmerku 400 mg/m2, temu pa 46-urna intravenska infuzija 5-FU v odmerku 2400 mg/m2.
Patients randomized to the lenalidomide/low dose dexamethasone arm received lenalidomide 25 mg/day, Days 1 to 21 every 28 days plus low dose dexamethasone – 40 mg/day on Days 1, 8, 15, and 22 every 28 days.
Bolniki, randomizirani na skupino lenalidomida/deksametazona v majhnem odmerku, so prejemali lenalidomid 25 mg/dan od 1. do 21. dne vsakih 28 dni plus deksametazon v majhnem odmerku – 40 mg/dan na 1., 8., 15. in 22. dan vsakih 28 dni.
Patients randomized to the lenalidomide/standard dose dexamethasone arm received lenalidomide
Bolniki, ki so bili randomizirani na skupino lenalidomida/deksametazona v standardnem odmerku, so prejemali lenalidomid 25 mg/dan od 1. do
Patients receive one Ozurdex implant at a time, injected directly into the vitreous humour.
Bolnik naenkrat prejme en vsadek zdravila Ozurdex, ki se injicira neposredno v steklovino.
Patients received 2 x 1000 mg intravenous infusions of MabThera or placebo in combination with MTX.
Bolniki so prejeli dve intravenski infuziji po 1.000 mg zdravila MabThera ali placeba v kombinaciji z metotreksatom.
Patients received a 300 mg loading dose of clopidogrel (600 mg possible if having PCI) or 180 mg of ticagrelor.
Bolniki so dobili 300-mg polnilni odmerek klopidogrela (600-mg odmerek je bil možen v primeru PCI) ali 180 mg tikagrelorja.
Patients received a maximum of six cycles of chemotherapy in each arm; patients in the Portrazza+GC arm who had no progression continued to receive single-agent Portrazza until disease progression, unacceptable toxicity, or withdrawal of consent.
Bolniki so v vsaki od skupin prejeli največ šest ciklov kemoterapije; bolniki v skupini Portrazza+GC, pri katerih bolezen ni napredovala, so še naprej prejemali zdravilo Portrazza v monoterapiji do napredovanja bolezni, nesprejemljive toksičnosti ali umika soglasja.
Patients received a mean of between 8.4-8.6 treatments out of possible 9 total across all treatment arms in the first year.
Bolniki v vseh krakih študije so v prvem letu dobili povprečno 8,4–8,6 odmerkov od skupno možnih 9.
Patients received a median of 4 cycles of maintenance treatment with pemetrexed and 4 cycles of placebo.
Bolniki so prejeli mediano 4 cikle vzdrževalnega zdravljenja s pemetreksedomin 4 cikle placeba.
Patients received a median treatment duration of 3.9 months in the Abraxane/gemcitabine arm and 2.8 months in the gemcitabine arm.
Mediana trajanja zdravljenja v skupini z zdravilom Abraxane/gemcitabinom je bila 3,9 meseca, v skupini z gemcitabinom pa 2,8 meseca.
Patients received a starting dose of Neparvis of 50 mg twice daily and were up-titrated to 100 mg twice daily, then to the target dose of 200 mg twice daily, with either a 3-week or a 6-week regimen.
Bolniki so prejemali začetni odmerek 50 mg zdravila Neparvis dvakrat na dan , nato pa so jim odmerek postopno zviševali najprej na 100 mg dvakrat na dan, nato pa na ciljni odmerek 200 mg dvakrat na dan v okviru bodisi 3-tedenskega ali 6-tedenskega režima.
Patients received a weight-based twice daily treatment regimen, patients weighing 10 kg to
Bolniki so prejeli odmerek dvakrat na dan, odvisno od telesne mase.
Patients received an initial dose of 80 mg Humira followed by 40 mg every other week (starting one week after the initial dose) or placebo for 16 weeks.
Bolniki so prejeli začetni odmerek 80 mg zdravila Humira, ki mu je sledil 40 mg odmerek ali placebo vsak drugi teden (z začetkom en teden po začetnem odmerku) naslednjih 16 tednov.
Patients received asparaginase at a dose of 10,000 U/m², adjusted to the current age of the patient at the time of administration (< 6 months: 6,700 U/m²; 6 – 12 months:
Bolniki so prejeli asparaginazo v odmerku 10.000 E/m², prilagojenem glede na trenutno starost bolnika v času dajanja (<6 mesecev: 6.700 E/m²;
Patients received Benlysta 10 mg/kg intravenously over a 1-hour period on Days 0, 14, 28, and then every 28 days for 52 weeks.
Bolniki so prejemali 10 mg/kg zdravila Benlysta intravensko 1 uro na dneve 0, 14 in 28 ter nato vsakih 28 dni 52 tednov.